PM/DM-ILD (n = 116) | Infection (n = 38) | Non-infection (n = 78) | P value | |
---|---|---|---|---|
Women (n (%)) | 24/38 (63.2%) | 59/78 (75.6%) | 0.16 | |
Type (n) | PM 7, DM 24, CADM 7 | PM 15, DM 27, CADM 36 | 0.007** | |
Age (years) | 58.9 ± 13.9c | 54.7 ± 15.2c | 0.15 | |
Baseline data | LDH (U/l) | 420 (335–574)d | 343 (258–486)d | 0.005** |
KL-6 (U/ml) | 848 (605–1231)d | 572 (405–978)d | 0.014* | |
CRP (mg/dl) | 0.9 (0.34–1.99)d | 0.30 (0.10–1.51)d | 0.032* | |
Lymphocyte (/μl) | 848 (552–1177)d | 1,008 (735–1435)d | 0.040* | |
Albumin (g/dl) | 3.18 ± 0.52c | 3.53 ± 0.55c | 0.003** | |
PaCO2 (mmHg) | 36.0 (31.5–38.8)d | 38.0 (35.5–41.5)d | 0.016* | |
HRCT | Zone A | 1.0 (0–2.0)d | 1.0 (0–1.0)d | 0.054 |
Zone B | 1.0 (1.0–2.0)d | 1.0 (0–1.0)d | 0.049* | |
Zone C | 2.0 (1.0–3.0)d | 1.0 (1.0–2.0)d | 0.036* | |
Zone D | 3.0 (2.0–4.0)d | 3.0 (2.0–4.0)d | 0.068 | |
Zone total | 7.0 (4.0–11.0)d | 6.0 (4.0–8.0)d | 0.031* | |
Treatment (n (%)) | Initial PSL dose (mg/kg/day) | 0.94 ± 0.30c | 0.76 ± 0.29c | 0.005** |
mPSL pulse (n (%)) | 31/38 (81.6%) | 46/78 (59.0%) | 0.016* | |
IVCY (n (%)) | 25/38 (65.8%) | 23/78 (29.5%) | <0.001** | |
Calcineurin inhibitor | 34/38 (89.5%) | 47/77 (61.0%) | 0.002** | |
Combination therapye | 23/38 (60.5%) | 17/78 (21.8%) | <0.001** | |
Outcome (n (%)) | Death | 11/38 (28.9%) | 3/78 (3.8%) | <0.001** |